drugset / Trial / NCT03980561

UH3 Varenicline for Cannabis Use Disorder

NCT03980561

Phase 2 Completed 174 enrolled Medical University of South Carolina
RandomizedParallel-groupDouble-blindTreatment

Summary

Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

Timeline

Start
2020-01-31
Primary completion
2023-02-09
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 2 mg

Indications